Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients
- 8 April 2014
- journal article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 73 (6), 1197-1204
- https://doi.org/10.1007/s00280-014-2456-2
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Analysis of Early Hypertension and Clinical Outcome With Bevacizumab: Results From Seven Phase III StudiesThe Oncologist, 2013
- Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertensionAnnals of Oncology, 2012
- Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2Otology & Neurotology, 2012
- Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapyThe Journal of Laryngology & Otology, 2011
- Effects of Novel Angiogenesis Inhibitors for the Treatment of Cancer on the Cardiovascular SystemCirculation, 2011
- Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a BiomarkerSeminars in Nephrology, 2010
- Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2Neuro-Oncology, 2009
- Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2The New England Journal of Medicine, 2009
- Neurofibromatosis type 2Journal of Medical Genetics, 2000
- Neurofibromatosis 1 (Recklinghausen Disease) and Neurofibromatosis 2 (Bilateral Acoustic Neurofibromatosis)Annals of Internal Medicine, 1990